28 April 2026
In plain English
Eli Lilly's new weight-loss pill Foundayo filled just 3,707 prescriptions in its second week on the market — compared with about 18,400 for Novo Nordisk's rival pill, oral Wegovy, in the same period. Lilly's stock fell on the data. For anyone watching the weight-loss drug race, Novo is winning the oral pill battle so far, even though Foundayo can be taken any time of day without fasting.
No new signals on the FDA's peptide advisory panel, which meets in 86 days with six empty seats still unfilled. Hims & Hers earnings on May 11 remain the next genuine test of whether the company's 49% stock rally is built on revenue or hope. On the pet side, a dog longevity startup called Loyal has now cleared two of three FDA hurdles — the farthest any dog lifespan-extension drug has ever gone. Quiet Monday otherwise.
Resolutions & upcoming
No forecasts resolved. No forecasts overdue. No forecasts resolving within 7 days.
Next 14-day catalyst: Hims & Hers Q1 2026 earnings on May 11 (13 days). Watch: peptide launch timeline guidance, free cash flow trajectory, California facility capex.
Resolution timeline: bpc157-pcac-2026 and pcac-july-multi-peptide on July 23 (86 days). compound-peptide-property-live on July 31 (94 days).
How Barque got smarter today
- Foundayo creates the first empirical oral GLP-1 head-to-head dataset. Prior runs discussed Foundayo conceptually; now IQVIA provides real prescription-count data. The 5x Wegovy advantage in Week 2 is a testable, trackable weekly signal. Consider proposing a market-share forecast to formalize tracking.
- LOY-002 closer than originally estimated. The dog-longevity-tracker opportunity was pegged as Phase 3 (2027 manufacturing trigger). With 2/3 FDA sections accepted and STAY enrollment complete, conditional approval could arrive late 2027. glp1pets is already positioned; the question is whether to build dedicated LOY-002 content now or wait.
- Menopause domain still dormant in forecast pipeline. Third day flagging: Ring 1 domain with no active forecasts. FDA HRT label softening and Lynkuet (Bayer, Oct 2025) as Veozah competitor reshape the market. Operator decision needed on whether to seed a menopause forecast.
- Sources sampled. Tier 1: FDA.gov (PCAC calendar, compounding lists), CMS.gov (Bridge), IQVIA via FiercePharma/Pharmaphorum/BiotechReality (Foundayo Rx), DVM360 (Akston, LOY-002), BusinessWire (Loyal). Tier 2: BioSpace, ManagedHealthcareExec, PetfoodIndustry, Smithsonian, Steve Dale PetWorld. Reddit fetch blocked (structural limitation persists).